<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598572</url>
  </required_header>
  <id_info>
    <org_study_id>2007P000288</org_study_id>
    <secondary_id>1R01NS057127-01A1</secondary_id>
    <nct_id>NCT00598572</nct_id>
  </id_info>
  <brief_title>Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage</brief_title>
  <acronym>DFO In ICH</acronym>
  <official_title>Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Animal studies show that the breakdown of blood results in iron accumulation in the brain&#xD;
      after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients.&#xD;
      Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to&#xD;
      remove excessive iron from the body, and has been shown to provide some benefit in animal&#xD;
      studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and&#xD;
      tolerability of treatment with DFO in patients with ICH, and to determine the maximal&#xD;
      tolerated dose to be used in future studies to determine if treatment with DFO can improve&#xD;
      the outcome of patients with ICH.&#xD;
&#xD;
      Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO,&#xD;
      by determining the treatment related adverse events, in patients with ICH; and 2) to&#xD;
      determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy&#xD;
      of DFO in improving outcome after ICH.&#xD;
&#xD;
      We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients&#xD;
      with ICH; and that treatment with DFO will improve patients' outcome. The results can&#xD;
      potentially bring into account new means to improve the outcome of patients with ICH. ICH is&#xD;
      a frequent cause of disability and death. A successful study demonstrating the efficacy of&#xD;
      iron-modifying therapy would be of considerable public health significance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, safety, tolerability, and dose-finding study using the continuous reassessment&#xD;
      method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>First 7 days of hospitalization or diacharge, whichever occurs earlier</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine Mesylate</intervention_name>
    <description>Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. The diagnosis of ICH is confirmed by brain CT scan.&#xD;
&#xD;
          3. The first dose of the study drug can be administered within 18 hours of ICH symptom&#xD;
             onset.&#xD;
&#xD;
          4. Signed and dated informed consent is obtained&#xD;
&#xD;
          5. Stable clinical and neurological status. Patients whose clinical or neurological&#xD;
             status significantly deteriorates compared to presentation prior to administration of&#xD;
             the study drug will be excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous chelation therapy or known hypersensitivity to DFO products&#xD;
&#xD;
          2. Abnormal renal function (serum creatinine &gt; 2 mg/dl)&#xD;
&#xD;
          3. Known severe iron deficiency anemia&#xD;
&#xD;
          4. Planned surgical evacuation of ICH prior to administration of the study drug&#xD;
&#xD;
          5. Patients with suspected secondary ICH related to tumour, coagulopathy, ruptured&#xD;
             aneurysm or arteriovenous malformation, or venous sinus thrombosis&#xD;
&#xD;
          6. Evidence of significant shift of midline brain structure (&gt; 10 mm) or herniation on&#xD;
             imaging studies.&#xD;
&#xD;
          7. Deep coma (Glasgow Coma Score (GCS) = 3-5) upon presentation&#xD;
&#xD;
          8. Taking iron supplements or prochlorperazine&#xD;
&#xD;
          9. Patients with heart failure taking &gt; 500 mg of vitamin C daily&#xD;
&#xD;
         10. Known hearing impairment&#xD;
&#xD;
         11. Systolic blood pressure &lt; 100 mmHg or diastolic blood pressure &lt; 60 mmHg, confirmed by&#xD;
             3 consecutive readings&#xD;
&#xD;
         12. Significant chronic respiratory insufficiency&#xD;
&#xD;
         13. Known pregnancy (or positive pregnancy test), or breast-feeding&#xD;
&#xD;
         14. Patients known or suspected of not being able to comply with the study protocol due to&#xD;
             alcoholism, drug dependency, incompliance, or any other cause.&#xD;
&#xD;
         15. Any condition which, in the judgement of the investigator, might increase the risk to&#xD;
             the patient&#xD;
&#xD;
         16. Life expectancy of less than 90 days due to co-morbid conditions&#xD;
&#xD;
         17. Concurrent participation in another research protocol for investigation of another&#xD;
             experimental therapy&#xD;
&#xD;
         18. Pre-existing Do Not Resuscitate (DNR) order, or indication that a new DNR order will&#xD;
             be implemented within the first 48 hours of hospitalization. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy Selim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Magdy Selim</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Deferoxamine</keyword>
  <keyword>Safety</keyword>
  <keyword>Intracerebral hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

